AARP Hearing Center
CLOSE
Search
Popular Searches
Suggested Links
Flexible Work
AARP Skills Builder
Flexible Work
ON-DEMAND WEBINARS
Drug Prices
Social Security
Medicare & Medicaid
Caregiving
LONG-TERM CARE
State Guides
Prepare to Care Guides
End of Life
Home Technology
Get Happier
POSSIBILITIES OF AI
Leaving AARP.org Website
You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
AARP Responds to Third Round of Drugs Selected for Medicare Drug Price Negotiation
Medicare now negotiates drug prices every year, thanks to the 2022 prescription drug law that AARP championed to bring down the cost of prescription drugs
WASHINGTON— Today, AARP CEO Dr. Myechia Minter-Jordan issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement of the next 15 drugs selected to have their prices negotiated by Medicare:
“AARP has long advocated for Medicare to negotiate prescription drug prices, and today’s announcement marks another significant step forward in that effort. Older Americans across the political spectrum consistently say that lowering drug prices is a top priority, and we thank the Administration for protecting Medicare’s ability to meet that need. As the voice for 125 million Americans age 50 and over, we will continue working to make prescription drugs more affordable.”
On January 22, 2026 AARP released:
- The Lifetime Price Increase report which found that list prices for the top 25 most expensive drugs covered by Medicare, and those not currently selected for Medicare drug price negotiation, have increased by an average of 67 percent since they first entered the market.
- And our most recent Rx survey of older adults showing that an overwhelming majority of older Americans want lawmakers to take the necessary steps to lower drug costs. Specifically:
· Nine in ten (91%) believe that reducing prescription drug prices and out-of-pocket costs should be a top priority for elected officials
· An even larger number (95%) think that Medicare should be allowed to negotiate directly with drug companies to lower the price of prescription medications..
· These findings hold across political party affiliation but are slightly higher for Democrats (96%, 97%) than Republicans (88%, 93%) and Independents (88%, 97%).
AARP’s December 18, 2025 Rx report also found that cost-sharing for the first 10 Medicare-negotiated drugs will decrease by an average of 50 percent for Medicare enrollees in 2026, thanks to the Medicare Drug Price Negotiation Program. The drugs are used by nearly 9 million Medicare seniors and treat conditions including diabetes, heart disease, autoimmune disorders, and cancer. The Medicare drug price negotiation program is expected to save enrollees $1.5 billion in out-of-pocket costs in 2026, according to the Centers for Medicare & Medicaid Services (CMS).
###
About AARP
AARP is the nation's largest nonprofit, nonpartisan organization dedicated to empowering people 50 and older to choose how they live as they age. With a nationwide presence, AARP strengthens communities and advocates for what matters most to the 125 million Americans 50-plus and their families: health and financial security, and personal fulfillment. AARP also produces the nation's largest-circulation publications: AARP The Magazine and the AARP Bulletin. To learn more, visit aarp.org, aarp.org/espanol or follow @AARP, @AARPLatino and @AARPadvocates on social media.
Media contact: Ilse Zuniga, izuniga@aarp.org